Trial · NCT07601737
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07601737, Phase 2, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma. Trials, record NCT07601737. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07601737
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
- NCT number
- NCT07601737
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 182 participants, estimated
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer, Neoadjuvant Therapy
- Interventions
- Nimotuzumab Injection, Tislelizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel, Cisplatin (Or Carboplatin), Radical surgery of tumor, Concurrent chemoradiotherapy
- First posted
- 2026-05-22
- Last updated
- 2026-07-09
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 2-Year Event-Free Survival (EFS) Rate | From first study treatment up to 2 years after the last patient randomized. | |
| Secondary | Major Pathologic Response (MPR) | Within 4 weeks after surgery. | |
| Secondary | Pathological Complete Response (pCR) | Within 4 weeks after surgery. | |
| Secondary | Objective Response Rate (ORR) | After 2 cycles (each cycle is 21 days） of neoadjuvant treatment. | |
| Secondary | 2-Year Overall Survival (OS) Rate | From first study treatment up to 2 years after the last patient randomized. | |
| Secondary | Quality of Life (QoL) | Baseline（Screening） After neoadjuvant chemotherapy：Study Group（S）Week6 /Control Group（C）NA Post-surgery：S Week 9/C Week 3 After adjuvant radiotherapy（S Week 21/C Week 15） End of treatment（Week 24） Follow-up: Month 6, Month 12, Month 24 | Assessed using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires QLQ-C30 (V3.0). EORTC QLQ-C30 V3.0：The scale consists of general domain items and global health and quality of life items. General domain items are further divided into functional domains and symptom domains. The raw scores of general items range from 1 (minimum) to 4 (maximum), while those of global health and quality of life items range from 1 (minimum) to 7 (maximum). All raw scores are finally standardized to scores ranging from 0 to 100. In functional domains including PF, RF, EF, CF, SF and QL, higher scores indicate better functional status. In symptom domains including FA, NV, PA, DY, SL, AP, CO, DI and FI, higher scores stand for more severe symptoms. For the global health and quality of life domain, higher scores reflect better general health condition and quality of life. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07601737
GET https://conductscience.org/api/trials/v1/NCT07601737/registered